SL-279252 is an experimental drug belonging to a new class of immunotherapies called “fusion proteins”. This means that the researchers have “fused” together two drugs to produce a single compound capable of targetting two different molecules with a single medication. This fusion protein works by targeting the molecules PD-L1 and OX40L.
Blocking PD-L1 serves to activate the body’s immune defences in order to target and destroy cancer cells. This is similar to a drug that is already used to treat Kidney Cancer, called Avelumab (Bavencio®).
Activating OX40L is a new approach to cancer treatment and may enhance the body’s immune response against cancerous cells by increasing the number of tumour-fighting white blood cells.
This study will investigate the safety and effectiveness of SL-279252 alone
In order to maximize effectiveness and minimize side effects, different doses of each drug will be used to determine the optimal dosage of these medications.
This is a single-group study, so there is no randomization, no placebo, and all patients will receive treatment.
- All subtypes eligible
- Advanced kidney cancer that cannot be removed by surgery
- No further drug treatments are available or recommended
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Center||Principal InvestigatorDr. Lillian Siu||LocationToronto, ON||Trial StatusRecruiting|